Ulcerative Colitis Therapeutics Pipeline Analysis, 2017

  • ID: 4340312
  • Report
  • 174 pages
  • P&S Market Research
1 of 3
Pipeline Overview

Ulcerative colitis is a chronic inflammatory disease, which basically affects colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The leading cause of ulcerative colitis is the imbalance in regulation of gastrointestinal immune system. According to the International Society for Pharmacoeconomic and Outcomes Research journal named as value in health, the prevalence of ulcerative colitis has increased from 243 to 263 per 100,000 people each year in the U.S. Ulcerative colitis usually affects the upper layer of all parts of intestine mostly in colon and rectum. The main causes of the disease are genetic susceptibility and environmental factors such as, microbiological, smoking, immunological and psychological factors.

The treatment of ulcerative colitis includes tumor necrosis factor inhibitors, such as adalimumab, golimumab and infliximab which were approved for treatment of moderate to severe form of ulcerative colitis in patients who has failed to respond to the other conventional therapies such as, corticosteroids, mesalazine and 5-Aminosalicylic acid. The 5-Aminosalicylic acid is currently used as the first line of therapy for ulcerative colitis and the number of reported cases of relapse of disease or refractory cases are very low.

As of April 2017, the ulcerative colitis pipeline comprised of approximately 89 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the last stage of development
  • Epidemiology Forecast - Epidemiology analysis and forecast
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Ulcerative Colitis Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Molecule Type
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Company

5. Ulcerative Colitis Therapeutics Pipeline Analysis By Phase (2017)
5.1 Filed: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Iii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase Ii: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Phase I: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Pre-Clinical: Drug Profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Strategic Development
5.5.4 Designation
5.5.5 Grants
5.5.6 Patent
5.5.7 Technology
5.6 Discovery: Drug Profiles
5.6.1 Strategic Development
5.6.2 Designation
5.6.3 Grants
5.6.4 Patent
5.6.5 Technology
5.7 Discontinued: Drug Candidates
5.8 Inactive: Drug Candidates

6 Competitive Landscape
6.1 Key Players Benchmarking For Ulcerative Colitis Therapeutic Candidates
6.2 Swot Analysis Of Ulcerative Colitis Therapeutics Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Ulcerative Colitis, By Company (2017)
Description Of Filed Drug Candidates
Clinical Trials Of Filed Drug Candidates
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Discontinued Drug Candidates
Inactive Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For The Ulcerative Colitis Therapeutics Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Number Of Ulcerative Colitis Drug Candidates Under Development (2017)
Ulcerative Colitis Pipeline Split, By Molecule Type (2017)
Ulcerative Colitis Pipeline Split, By Route Of Administration (2017)
Key Players Benchmarking For Ulcerative Colitis Drug Candidates
Swot Analysis Of Ulcerative Colitis Therapeutics Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll